Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.77 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633816 | 0.87 | HTR6 (0.77) | HTR6ESR1FBP1ALDH1A1 | |
| SCHEMBL1635040 | 0.87 | HTR6 (1.00) | HTR6ESR1FBP1KMT2ATSHR | |
| SCHEMBL1633740 | 0.86 | HTR6 (0.76) | HTR6ESR1FBP1ALDH1A1 | |
| SCHEMBL1635033 | 0.84 | HTR6 (0.72) | HTR6ESR1KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL1633675 | 0.78 | HTR6 (0.63) | HTR6KEAP1NFE2L2FBP1KMT2A | |
| SCHEMBL1634443 | 0.77 | HTR6 (0.63) | HTR6ESR1KEAP1FBP1ALDH1A1 | |
| SCHEMBL7595505 | 0.72 | KEAP1 (0.59) | KEAP1NFE2L2MEN1KMT2ATSHR | |
| SCHEMBL24715417 | 0.72 | HTR6 (0.47) | HTR6ESR1 | |
| SCHEMBL7594942 | 0.68 | KEAP1 (0.62) | KEAP1NFE2L2MEN1KMT2ATSHR | |
| SCHEMBL115237 | 0.68 | PIK3CD (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| CN-101945877-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2011-01-12 | — | — | CN | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | HTR6 4366/4885ESR1 3635/4885KEAP1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.